Publications
Detailed Information
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Seung Tae | - |
dc.contributor.author | Hong, Yong Sang | - |
dc.contributor.author | Lim, Ho Yeong | - |
dc.contributor.author | Lee, Jeeyun | - |
dc.contributor.author | Kim, Tae Won | - |
dc.contributor.author | Kim, Kyu-Pyo | - |
dc.contributor.author | Kim, Sun Young | - |
dc.contributor.author | Baek, Ji Yeon | - |
dc.contributor.author | Kim, Jee Hyun | - |
dc.contributor.author | Lee, Keun-Wook | - |
dc.contributor.author | Chung, Ik-Joo | - |
dc.contributor.author | Cho, Sang-Hee | - |
dc.contributor.author | Lee, Kyung Hee | - |
dc.contributor.author | Shin, Sang Joon | - |
dc.contributor.author | Kang, Hye Jin | - |
dc.contributor.author | Shin, Dong Bok | - |
dc.contributor.author | Lee, Jae Won | - |
dc.contributor.author | Jo, Sook Jung | - |
dc.contributor.author | Park, Young Suk | - |
dc.date.accessioned | 2017-02-07T08:54:31Z | - |
dc.date.available | 2017-02-07T08:54:31Z | - |
dc.date.issued | 2014-11-26 | - |
dc.identifier.citation | BMC Cancer, 14(1):883 | ko_KR |
dc.identifier.uri | https://hdl.handle.net/10371/100510 | - |
dc.description | This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. | ko_KR |
dc.description.abstract | Abstract
Background We report updated progression-free survival (PFS) and overall survival (OS) data from a trial that compared capecitabine plus oxaliplatin (CapeOX) versus S-1 plus oxaliplatin (SOX) for the first-line treatment of metastatic colorectal cancer. Methods This trial was a randomized, two-armed, non-inferiority phase 3 comparison of CapeOX (capecitabine 1000 mg/m2 twice daily on days 1–14 and oxaliplatin 130 mg/m2 on day 1) versus SOX (S-1 40 mg/m2 twice daily on days 1–14 and oxaliplatin 130 mg/m2 on day 1). The primary end point was to show non-inferiority of SOX relative to CapeOX in terms of PFS. Thus, a follow-up exploratory analysis of PFS and OS was performed. Results The intention to treat (ITT) population was comprised of 340 patients (SOX arm: 168 and CapeOX arm: 172). The updated median PFS was 7.1 months (95% CI 6.4-8.0) in the SOX group and 6.3 months (95% CI 4.9-6.7) in the CapeOX group (hazard ratio [HR], 0.83 [0.66-1.04], p = .10). The median OS was 19.0 months (95% CI 15.3-23.0) in the SOX group and 18.4 months (95% CI 14.1-20.7) in the CapeOX group (HR, 0.86 [0.68-1.08], p = .19). Subgroup analyses according to principal demographic factors such as sex, age, ECOG (Eastern Cooperative Oncology Group) performance status, primary tumor location, measurability, previous adjuvant therapy, number of metastatic organs, and liver metastases showed no interaction between any of these characteristics and the treatment. Conclusions Updated survival analysis shows that SOX is similar to CapeOX, confirming the initial PFS analysis. Therefore, the SOX regimen could be an alternative first-line doublet chemotherapy strategy for patients with metastatic colorectal cancer. Trial registration NCT00677443 and May 12 2008 | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | BioMed Central | ko_KR |
dc.subject | Capecitabine | ko_KR |
dc.subject | S-1 | ko_KR |
dc.subject | Colorectal cancers | ko_KR |
dc.title | S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 김승태 | - |
dc.contributor.AlternativeAuthor | 홍용상 | - |
dc.contributor.AlternativeAuthor | 임호영 | - |
dc.contributor.AlternativeAuthor | 이지연 | - |
dc.contributor.AlternativeAuthor | 김태원 | - |
dc.contributor.AlternativeAuthor | 김규표 | - |
dc.contributor.AlternativeAuthor | 김선영 | - |
dc.contributor.AlternativeAuthor | 백지연 | - |
dc.contributor.AlternativeAuthor | 김지현 | - |
dc.contributor.AlternativeAuthor | 이근욱 | - |
dc.contributor.AlternativeAuthor | 정익주 | - |
dc.contributor.AlternativeAuthor | 조상희 | - |
dc.contributor.AlternativeAuthor | 이경희 | - |
dc.contributor.AlternativeAuthor | 신상준 | - |
dc.contributor.AlternativeAuthor | 강혜진 | - |
dc.contributor.AlternativeAuthor | 신동복 | - |
dc.contributor.AlternativeAuthor | 이재원 | - |
dc.contributor.AlternativeAuthor | 조숙정 | - |
dc.contributor.AlternativeAuthor | 박영숙 | - |
dc.identifier.doi | 10.1186/1471-2407-14-883 | - |
dc.language.rfc3066 | en | - |
dc.rights.holder | Kim et al.; licensee BioMed Central Ltd. | - |
dc.date.updated | 2017-01-06T10:10:24Z | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.